ATRA vs. PRQR, INBX, CYBN, IVVD, NBTX, DRUG, PLRX, GNLX, SCPH, and LYEL
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include ProQR Therapeutics (PRQR), Inhibrx (INBX), Cybin (CYBN), Invivyd (IVVD), Nanobiotix (NBTX), Bright Minds Biosciences (DRUG), Pliant Therapeutics (PLRX), Genelux (GNLX), scPharmaceuticals (SCPH), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.
Atara Biotherapeutics vs.
Atara Biotherapeutics (NASDAQ:ATRA) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
Atara Biotherapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.
Atara Biotherapeutics has a net margin of -132.58% compared to ProQR Therapeutics' net margin of -134.31%. Atara Biotherapeutics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.
Atara Biotherapeutics received 104 more outperform votes than ProQR Therapeutics when rated by MarketBeat users. Likewise, 67.28% of users gave Atara Biotherapeutics an outperform vote while only 61.71% of users gave ProQR Therapeutics an outperform vote.
70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 3.7% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Atara Biotherapeutics presently has a consensus price target of $17.75, suggesting a potential upside of 149.65%. ProQR Therapeutics has a consensus price target of $8.83, suggesting a potential upside of 245.05%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Atara Biotherapeutics.
ProQR Therapeutics has lower revenue, but higher earnings than Atara Biotherapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ProQR Therapeutics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 2 mentions for ProQR Therapeutics and 0 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.10 beat ProQR Therapeutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media.
Summary
Atara Biotherapeutics and ProQR Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atara Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATRA) was last updated on 2/22/2025 by MarketBeat.com Staff
